462 related articles for article (PubMed ID: 31385078)
1. High bisphosphonate treatment rates and the prevalence of atypical femoral fractures in patients with systematic lupus erythematosus: a single-center retrospective study performed in Japan.
Sato H; Kondo N; Wakamatsu A; Kobayashi D; Nakatsue T; Wada Y; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Rheumatol Int; 2019 Oct; 39(10):1803-1810. PubMed ID: 31385078
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D and bisphosphonate therapy in systemic lupus erythematosus patients who receive glucocorticoids: are we offering the best care?
Sapkota S; Baig S; Hess T; O'Connell AM; Menk J; Shyne M; Fazeli P; Ensrud K; Shmagel A
Lupus; 2020 Mar; 29(3):263-272. PubMed ID: 31996109
[TBL] [Abstract][Full Text] [Related]
3. Predisposing factors associated with atypical femur fracture among postmenopausal Korean women receiving bisphosphonate therapy: 8 years' experience in a single center.
Koh JH; Myong JP; Yoo J; Lim YW; Lee J; Kwok SK; Park SH; Ju JH
Osteoporos Int; 2017 Nov; 28(11):3251-3259. PubMed ID: 28748389
[TBL] [Abstract][Full Text] [Related]
4. High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.
Sato H; Kondo N; Nakatsue T; Wada Y; Fujisawa J; Kazama JJ; Kuroda T; Suzuki Y; Nakano M; Endo N; Narita I
Osteoporos Int; 2017 Aug; 28(8):2367-2376. PubMed ID: 28409215
[TBL] [Abstract][Full Text] [Related]
5. The cumulative incidence of and risk factors for latent beaking in patients with autoimmune diseases taking long-term glucocorticoids and bisphosphonates.
Sato H; Kondo N; Wada Y; Nakatsue T; Iguchi S; Fujisawa J; Kazama JJ; Kuroda T; Nakano M; Endo N; Narita I
Osteoporos Int; 2016 Mar; 27(3):1217-1225. PubMed ID: 26519417
[TBL] [Abstract][Full Text] [Related]
6. Incidence and medical management of bisphosphonate-associated atypical femoral fractures in a major trauma centre: a retrospective observational study.
Eisenstein N; Kasavkar G; Bhavsar D; Khan FS; Paskins Z
BMC Musculoskelet Disord; 2017 Jan; 18(1):29. PubMed ID: 28114975
[TBL] [Abstract][Full Text] [Related]
7. Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease.
Lai KH; Chiang CY; Yang RS; Yang KC; Wu CC
Acta Clin Belg; 2019 Oct; 74(5):370-374. PubMed ID: 30336748
[No Abstract] [Full Text] [Related]
8. Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.
Lo JC; Grimsrud CD; Ott SM; Chandra M; Hui RL; Ettinger B
Osteoporos Int; 2019 Dec; 30(12):2515-2520. PubMed ID: 31555883
[TBL] [Abstract][Full Text] [Related]
9. Trends in the incidence of atypical femoral fractures and bisphosphonate therapy.
Clout A; Narayanasamy N; Harris I
J Orthop Surg (Hong Kong); 2016 Apr; 24(1):36-40. PubMed ID: 27122510
[TBL] [Abstract][Full Text] [Related]
10. Incidence Rate of Atypical Femoral Fracture after Bisphosphonates Treatment in Korea.
Lee YK; Ahn S; Kim KM; Suh CS; Koo KH
J Korean Med Sci; 2018 Jan; 33(5):e38. PubMed ID: 29349947
[TBL] [Abstract][Full Text] [Related]
11. T-Score Discordance of Bone Mineral Density in Patients with Atypical Femoral Fracture.
Lee KJ; Min BW; Song KS; Bae KC; Cho CH; Lee SW
J Bone Joint Surg Am; 2017 Oct; 99(19):1683-1688. PubMed ID: 28976433
[TBL] [Abstract][Full Text] [Related]
12. Natural history of incomplete atypical femoral fractures in patients after a prolonged and variable course of bisphosphonate therapy-a long-term radiological follow-up.
Png MA; Mohan PC; Koh JSB; Howe CY; Howe TS
Osteoporos Int; 2019 Dec; 30(12):2417-2428. PubMed ID: 31435684
[TBL] [Abstract][Full Text] [Related]
13. Fracture risk in systemic lupus erythematosus patients over 28 years.
Garelick D; Pinto SM; Farinha F; Pires T; Khan E; Isenberg D
Rheumatology (Oxford); 2021 Jun; 60(6):2765-2772. PubMed ID: 33221918
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for development of atypical femoral fractures in patients on long-term oral bisphosphonate therapy.
Franceschetti P; Bondanelli M; Caruso G; Ambrosio MR; Lorusso V; Zatelli MC; Massari L; Degli Uberti EC
Bone; 2013 Oct; 56(2):426-31. PubMed ID: 23871850
[TBL] [Abstract][Full Text] [Related]
15. ATYPICAL FEMORAL FRACTURES AFTER LONG-TERM BISPHOSPHONATES THERAPY: CASE REPORT.
Găleşanu C; Mocanu V; Buzdugă C; Florescu A; Zaharia V; Lisnic V
Rev Med Chir Soc Med Nat Iasi; 2016; 120(1):114-8. PubMed ID: 27125082
[TBL] [Abstract][Full Text] [Related]
16. The association of race/ethnicity and risk of atypical femur fracture among older women receiving oral bisphosphonate therapy.
Lo JC; Hui RL; Grimsrud CD; Chandra M; Neugebauer RS; Gonzalez JR; Budayr A; Lau G; Ettinger B
Bone; 2016 Apr; 85():142-7. PubMed ID: 26769007
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates and the risk of atypical femur fractures.
Black DM; Condra K; Adams AL; Eastell R
Bone; 2022 Mar; 156():116297. PubMed ID: 34920168
[TBL] [Abstract][Full Text] [Related]
18. Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.
van de Laarschot DM; McKenna MJ; Abrahamsen B; Langdahl B; Cohen-Solal M; Guañabens N; Eastell R; Ralston SH; Zillikens MC
J Clin Endocrinol Metab; 2020 May; 105(5):1682-99. PubMed ID: 31867670
[TBL] [Abstract][Full Text] [Related]
19. Trabecular Bone Score and Hip Structural Analysis in Patients With Atypical Femur Fractures.
Buitendijk SKC; van de Laarschot DM; Smits AAA; Koromani F; Rivadeneira F; Beck TJ; Zillikens MC
J Clin Densitom; 2019; 22(2):257-265. PubMed ID: 29661684
[TBL] [Abstract][Full Text] [Related]
20. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide.
Miyakoshi N; Aizawa T; Sasaki S; Ando S; Maekawa S; Aonuma H; Tsuchie H; Sasaki H; Kasukawa Y; Shimada Y
J Bone Miner Metab; 2015 Sep; 33(5):553-9. PubMed ID: 25227287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
